takeda Archives

ive professionals meet around a conference table with laptops and calendars, beside a whiteboard highlighting December EoE data and EPRX.

Eupraxia: A Packed Investor Calendar Sets the Table for December EoE Data -( $EPRX $IBB $REGN $SNY $TAK $XBI )

by John F. Heerdink, Jr. October 27, 2026 373Views 0Likes

With its 120-patient target reached, encouraging early durability data and a November investor calendar, Eupraxia Pharmaceuticals is building a more substantial case for long-acting drug delivery. Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) is approaching the kind of stretch that can move a…

Iambic’s $150 Million IPO Puts AI Drug Discovery in Wall Street’s Spotlight -( $IAM $IBB $JNJ $LLY $NVDA $TAK $XBI )

by John F. Heerdink, Jr. October 12, 2026 934Views 0Likes

Nvidia-backed biotech pairs a clinical-stage cancer pipeline with pharmaceutical partnerships as TRex Bio, Retension and Lycia join the IPO queue October 8, 2026 Artificial intelligence has spent the past several years promising to transform drug discovery. Iambic Therapeutics is now asking Wall…

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

by John F. Heerdink, Jr. March 25, 2026 745Views 0Likes

Yes indeed, Eupraxia Pharmaceutical's (NASDAQ: EPRX) EP-104 is quietly auditioning for a starring role in eosinophilic esophagitis—and for once, the gastroenterologist, the allergist, and the payer might actually clap at the same time. A Chronic Disease Finally Meets a Long-Term Plan Eosinophilic…

Tag: takeda

Eupraxia: A Packed Investor Calendar Sets the Table for December EoE Data -( $EPRX $IBB $REGN $SNY $TAK $XBI )

Iambic’s $150 Million IPO Puts AI Drug Discovery in Wall Street’s Spotlight -( $IAM $IBB $JNJ $LLY $NVDA $TAK $XBI )

Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI )

Your Guide To Staying Informed In The Markets